Background: The current prospective, randomized, controlled REVERSE-FLOW trial aims to systematically examine the effect of the glycoprotein (GP) IIb/IIIa inhibitors on infarct size in patients with STEMI and NSTEMI and angiographic evidence of no-reflow. Trial Registration No: SNCTP000003611 Trial Status: active Enrolling Centers: 5 Core Study Team:
© Christian Mueller, 2012 - 2021 │ DisclaimerImprintWebmaster │ Last Update: May 2021
Dr. Gregor Fahrni Dr. Philip Haaf Ina-Maria Ferel Ph.D. Beate Hartmann Ph.D